UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.87M | 90.40M | 89.36M | 85.01M | 84.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.87M | 90.40M | 89.36M | 85.01M | 84.30M |
| Cost of Revenue | 9.48M | 8.88M | 8.70M | 8.61M | 8.82M |
| Gross Profit | 82.39M | 81.52M | 80.67M | 76.40M | 75.48M |
| SG&A Expenses | 127.72M | 120.05M | 110.85M | 103.66M | 96.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.73M | 186.08M | 173.10M | 164.70M | 153.53M |
| Operating Income | -106.86M | -95.68M | -83.73M | -79.69M | -69.23M |
| Income Before Tax | -135.26M | -124.04M | -111.34M | -109.65M | -100.36M |
| Income Tax Expenses | 3.17M | 2.83M | 4.04M | 3.94M | 3.95M |
| Earnings from Continuing Operations | -138.43 | -126.87 | -115.38 | -113.58 | -104.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.43M | -126.87M | -115.38M | -113.58M | -104.32M |
| EBIT | -106.86M | -95.68M | -83.73M | -79.69M | -69.23M |
| EBITDA | -106.58M | -95.35M | -83.28M | -79.12M | -68.52M |
| EPS Basic | -3.18 | -3.13 | -3.05 | -3.18 | -3.30 |
| Normalized Basic EPS | -1.93 | -1.90 | -1.84 | -1.92 | -1.99 |
| EPS Diluted | -3.18 | -3.13 | -3.05 | -3.18 | -3.30 |
| Normalized Diluted EPS | -1.93 | -1.90 | -1.84 | -1.92 | -1.99 |
| Average Basic Shares Outstanding | 174.38M | 164.01M | 153.13M | 142.33M | 128.97M |
| Average Diluted Shares Outstanding | 174.38M | 164.01M | 153.13M | 142.33M | 128.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |